Frequency of Diabetes-Related Complications in Type 1 and Type 2 Diabetes—Results from the International Diabetes Management Practices Study (IDMPS)
Authors: GAGLIARDINO JUAN J. , ASCHNER PABLO , ILKOVA HASAN M. , LAVALLE-GONZALEZ FERNANDO J. , RAMACHANDRAN AMBADY , KADDAHA GHAIDA , MBANYA JEAN CLAUDE , SHESTAKOVA MARINA V. , CHANTELOT JEAN-MARC , CHAN JULIANA C. 
Published: June 2018

Complications associated with diabetes have a considerable negative impact on patient wellbeing and economic contribution, and place a large burden on healthcare and welfare systems. Annual screening for diabetes-related complications is recommended in treatment guidelines. The IDMPS is a global observational survey on the management and patterns of care of people with type 1 (T1D) and type 2 (T2D) diabetes in the developing world. We report details of the burden of the disease in 2016-17 in 24 countries across Africa, the Middle East, South Asia, and Eurasia. Physician-reported annual screening rates for diabetes-related complications of the eye (retina examination), nerve (monofilament test), kidney (blood or urine test), foot (ulcer examination), blood pressure (SBP/DBP), and metabolism (lipid profile test) ranged from 62.5-94.3% (Table). High rates of complications were recorded (independent of screening); microvascular complications (eye, nervous system, and kidney) were reported in almost 50% of people with T1D or T2D; macrovascular complications (heart conditions and stroke) were reported in 5.9% and 16.0% of people, respectively. Screening for diabetes-related complications in the developing world is not universal. Dedication of more resources to screening may reduce the rates of development or worsening of complications.

Disclosure
J.J. Gagliardino: Other Relationship; Self; Sanofi. P. Aschner: Other Relationship; Self; Sanofi. H.M. Ilkova: Advisory Panel; Self; Abbott, Eli Lilly and Company, Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim GmbH, Servier, Merck Sharp & Dohme Corp.. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Medtronic, Roche Diabetes Care Health and Digital Solutions, Bilim İlac. F.J. Lavalle-Gonzalez: Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; Novo Nordisk Inc.. Advisory Panel; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Research Support; Self; AstraZeneca. Advisory Panel; Self; Merck Sharp & Dohme Corp.. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Abbott. Speaker's Bureau; Self; Abbott. A. Ramachandran: None. G. Kaddaha: Other Relationship; Self; Sanofi. J. Mbanya: Advisory Panel; Self; GlaxoSmithKline plc.. Speaker's Bureau; Self; Novo Nordisk A/S, Sanofi, Servier. M.V. Shestakova: None. J. Chantelot: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. J.C. Chan: Consultant; Self; Bayer AG. Other Relationship; Self; Bayer AG. Consultant; Self; Sanofi. Other Relationship; Self; Sanofi, Eli Lilly and Company, Amgen Inc.. Consultant; Self; AstraZeneca, Merck & Co., Inc., Pfizer Inc.. Other Relationship; Self; Pfizer Inc.. Board Member; Self; Asia Diabetes Foundation. Stock/Shareholder; Self; GemVCare. Other Relationship; Self; Merck Sharp & Dohme Corp.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Novartis AG, Eli Lilly and Company.